André Luís Morais Ruela

Dr. André Luís Morais Ruela

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Brazilian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
ARAndré Luís Morais Ruela
André Luís Morais Ruela
APAline Gravinez Perissinato
Aline Gravinez Perissinato
MLMônica Esselin de Sousa Lino
Mônica Esselin de Sousa Lino
PMPaula Silva Mudrik
Paula Silva Mudrik
GPGislaine Ribeiro Pereira
Gislaine Ribeiro Pereira
The skin barrier function has been attributed to the stratum corneum and represents a major challenge in clinical practice pertaining to cutaneous administration of drugs. Despite this, a large number of bioactive compounds have been successfully administered via cutaneous administration because of advances in the design of topical and transdermal formulations. In vitro and in vivo evaluations of these novel drug delivery systems are necessary to characterize their quality and efficacy. This review covers the most well-known methods for assessing the cutaneous absorption of drugs as an auxiliary tool for pharmaceutical formulation scientists in the design of drug delivery systems. In vitro methods as skin permeation assays using Franz-type diffusion cells, cutaneous retention and tape-stripping methods to study the cutaneous penetration of drugs, and in vivo evaluations as pre-clinical pharmacokinetic studies in animal models are discussed. Alternative approaches to cutaneous microdialysis are also covered. Recent advances in research on skin absorption of drugs and the effect of skin absorption enhancers, as investigated using confocal laser scanning microscopy, Raman confocal microscopy, and attenuated total reflectance Fourier-transform infrared spectroscopy, are reviewed.

1 April 2021 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
AMAnanda Pulini Matarazzo
Ananda Pulini Matarazzo
LELívia Maria Silvestre Elisei
Lívia Maria Silvestre Elisei
FCFlávia Chiva Carvalho
Flávia Chiva Carvalho
RBRudy Bonfílio
Rudy Bonfílio
ARAndré Luís Morais Ruela
André Luís Morais Ruela
GPGislaine Ribeiro Pereira
Gislaine Ribeiro Pereira

1 July 2014 in Chemical Engineering Journal
Verified
Journal Article
Closed access
ARAndré Luís Morais Ruela
André Luís Morais Ruela
EFEduardo Costa Figueiredo
Eduardo Costa Figueiredo
GPGislaine Ribeiro Pereira
Gislaine Ribeiro Pereira

1 January 2016 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
ARAndré Luís Morais Ruela
André Luís Morais Ruela
FCFlávia Carvalho
Flávia Carvalho
GPGislaine Ribeiro Pereira
Gislaine Ribeiro Pereira

1 July 2021 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
ISIsabelly Fernanda Ferraz de Souza
Isabelly Fernanda Ferraz de Souza
TSThaís Queiroz dos Santos
Thaís Queiroz dos Santos
RPRodrigo Vicentino Placido
Rodrigo Vicentino Placido
BMBianca Aparecida Mangerona
Bianca Aparecida Mangerona
FCFlávia Carvalho
Flávia Carvalho
GPGislaine Ribeiro Pereira
Gislaine Ribeiro Pereira

8 February 2018 in Critical Reviews in Analytical Chemistry
Verified
Journal Article
Closed access
MÂMarilene Lopes Ângelo
Marilene Lopes Ângelo
Fernanda MoreiraFernanda Moreira
Fernanda Moreira
ARAndré Luís Morais Ruela
André Luís Morais Ruela
MAMagali Benjamim Araújo
Magali Benjamim Araújo
HSHérida Regina Nunes Salgado
Hérida Regina Nunes Salgado
MAMagali Benjamim de Araújo
Magali Benjamim de Araújo
Rosuvastatin calcium (ROS), (Figure 1) belongs to the “statins” group, which is the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. This drug is indicated for dyslipidemias treatment and can help to decrease the level of “bad cholesterol” and can consequently reduce the development of atherosclerosis and the risk of heart diseases. ROS was developed by Astra-Zeneca and it was approved in 2003 by the FDA in the United States. In 2015, under the trade name Crestor®, it was the fourth largest selling drug in the United States with sales above $5 billion. This study presents a literature review of analytical methods for the quantification of ROS in pharmaceutical preparations and biological fluids. The major analytical methods described in this study for ROS were spectrophotometry, high-performance liquid chromatography (HPLC) coupled to ultraviolet (UV) detection, and tandem mass spectrometry (LC–MS/MS).